News | January 23, 2025
Dr Reddy’s Labs Q3 FY25 profit up 2% YoY at Rs. 1,413 Cr
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
In 2023, Endox had revenues of approximately SEK 65 million
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The scheme is fully digitized and covers approximately 45% of India's population
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
